Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP066
MIFTS: 63

Hyperglycemia

Categories: Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hyperglycemia

About this section

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 76 29 55 6 43 44 15 73

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Hyperglycemia

About this section
MedlinePlus : 43 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, transient neonatal, 1 and maturity-onset diabetes of the young, type 2, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1
Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Developmental Biology and Aldosterone synthesis and secretion. The drugs Zinc and Glipizide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and testes, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 76 Hyperglycemia, or high blood sugar (also spelled hyperglycaemia or hyperglycæmia) is a condition in... more...

Sources

Related Diseases for Hyperglycemia

About this section

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, transient neonatal, 1 33.5 ABCC8 INS KCNJ11
2 maturity-onset diabetes of the young, type 2 33.0 GCK INS
3 diabetes mellitus, permanent neonatal 32.4 ABCC8 GCK INS KCNJ11 PDX1
4 hyperinsulinism 31.3 ABCC8 GCK IGF1 INS INSR KCNJ11
5 hypoglycemia 31.0 ABCC8 GCG GCK INS INSR KCNJ11
6 microvascular complications of diabetes 5 31.0 AKR1B1 IGF1 INS
7 fanconi-bickel syndrome 30.6 ABCC8 INS SLC2A2
8 microvascular complications of diabetes 3 30.5 AKR1B1 INS MALAT1
9 acromegaly 30.5 IGF1 INS SST
10 hyperandrogenism 30.4 IGF1 INS INSR
11 insulin-like growth factor i 30.3 IGF1 INS INSR LEP
12 arteries, anomalies of 30.3 ADIPOQ INS LEP PPARG
13 lipodystrophy, familial partial, type 2 30.2 INS LEP
14 polycystic ovary syndrome 30.1 IGF1 INS INSR LEP
15 chronic kidney failure 30.1 ADIPOQ IGF1 INS LEP
16 atherosclerosis susceptibility 30.1 ADIPOQ INS PPARG
17 diabetes mellitus, insulin-dependent 30.1 AKR1B1 GCG GCK HNF1A IAPP IGF1
18 gestational diabetes 29.9 ADIPOQ GCK HNF1A INS INSR KCNJ11
19 hyperthyroidism 29.9 INS LEP SST
20 abdominal obesity-metabolic syndrome 1 29.8 ADIPOQ INS LEP PPARG
21 monogenic diabetes 29.8 ABCC8 GCK HNF1A INS KCNJ11 PDX1
22 glucose intolerance 29.5 ADIPOQ DPP4 GCG GCK IGF1 INS
23 neonatal diabetes mellitus 29.5 ABCC8 GCK INS KCNJ11 PDX1 SLC2A2
24 insulinoma 29.0 ABCC8 GCG GCK IAPP INS PDX1
25 fatty liver disease 28.8 ADIPOQ INS INSR LEP MALAT1 PPARG
26 maturity-onset diabetes of the young 28.5 ABCC8 DPP4 GCG GCK HNF1A IAPP
27 diabetes mellitus, noninsulin-dependent 26.3 ABCC8 ADIPOQ AKR1B1 DPP4 GCG GCK
28 diabetes mellitus 26.1 ABCC8 ADIPOQ AKR1B1 DPP4 GCG GCK
29 diabetes mellitus, ketosis-prone 11.2
30 diabetes and deafness, maternally inherited 11.2
31 insulin autoimmune syndrome 11.1 INS INSR
32 type 1 diabetes mellitus 15 11.1 GCG INS
33 munchausen by proxy 11.0 ABCC8 GCK KCNJ11
34 maturity-onset diabetes of the young, type 3 11.0 HNF1A INS
35 mitochondrial complex iii deficiency, nuclear type 6 11.0
36 acidophil adenoma 11.0 IGF1 SST
37 secondary adrenal insufficiency 11.0 IGF1 INS
38 dumping syndrome 10.9 GCG INS SST
39 duodenal somatostatinoma 10.9 INS SST
40 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.9 IGF1 INS INSR
41 pituitary infarct 10.9 IGF1 SST
42 postgastrectomy syndrome 10.9 INS SST
43 donohue syndrome 10.9 IGF1 INS INSR
44 pancreas, dorsal, agenesis of 10.9
45 cardiomyopathy, dilated, 1o 10.9 ABCC8 KCNJ11
46 postural hypotension 10.9 INS SST
47 hyperpituitarism 10.9 IGF1 INS SST
48 factitious disorder 10.9 ABCC8 GCK INS KCNJ11
49 idiopathic edema 10.9 ADIPOQ INS PPARG
50 acute insulin response 10.9 ABCC8 GCG INS KCNJ11

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia
Sources

Symptoms & Phenotypes for Hyperglycemia

About this section

UMLS symptoms related to Hyperglycemia:


cachexia, cyanosis, dyspnea, edema, fever, headache, icterus, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.36 GCK INS HNF1A ADIPOQ IAPP AKR1B1
2 homeostasis/metabolism MP:0005376 10.36 GCK INS ABCC8 HNF1A ADIPOQ IAPP
3 endocrine/exocrine gland MP:0005379 10.29 GCK ABCC8 HNF1A ADIPOQ IGF1 DPP4
4 behavior/neurological MP:0005386 10.27 HNF1A ADIPOQ AKR1B1 SLC2A2 SLC5A2 SST
5 mortality/aging MP:0010768 10.17 GCK HNF1A ADIPOQ AKR1B1 IGF1 SLC2A2
6 adipose tissue MP:0005375 10.16 HNF1A ADIPOQ IGF1 SLC5A2 INS LEP
7 liver/biliary system MP:0005370 10.02 GCK HNF1A ADIPOQ SLC2A2 PPARG INS
8 integument MP:0010771 10.01 IGF1 HNF1A ADIPOQ PPARG KCNJ11 INS
9 muscle MP:0005369 9.96 HNF1A ADIPOQ IGF1 SLC2A2 PPARG INS
10 no phenotypic analysis MP:0003012 9.81 ABCC8 HNF1A SLC5A2 SST UNC13B KCNJ11
11 renal/urinary system MP:0005367 9.7 GCK INS HNF1A ADIPOQ AKR1B1 IGF1
12 skeleton MP:0005390 9.32 IGF1 HNF1A ADIPOQ IAPP AKR1B1 PPARG
Sources

Drugs & Therapeutics for Hyperglycemia

About this section

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 811)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
2
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2 29094-61-9 3478
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
4
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
5
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
6
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Not Applicable 169148-63-4 5311023
7
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Not Applicable 207748-29-6
8
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
9
Insulin Lispro Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 133107-64-9
10
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56180-94-0 441184
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
12
Curcumin Approved, Investigational Phase 4,Phase 2,Phase 3 458-37-7 969516
13
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
14 Parecoxib Approved Phase 4 198470-84-7
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
17
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
18
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
19
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
20
Nitric Oxide Approved Phase 4,Not Applicable 10102-43-9 145068 160954
21
Amlodipine Approved Phase 4 88150-42-9 2162
22
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
23
Atenolol Approved Phase 4 29122-68-7 2249
24
Clonidine Approved Phase 4 4205-90-7 2803
25
Doxazosin Approved Phase 4 74191-85-8 3157
26
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
27
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
28
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
29
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
30
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
31
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
32
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
33
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-23-7 5754
34
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
36
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
37
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
38
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
40
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
41
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
42
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
43
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
44
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
46
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
47
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
48
Fenofibrate Approved Phase 4,Phase 2,Phase 3,Not Applicable 49562-28-9 3339
49
Linagliptin Approved Phase 4,Phase 3,Not Applicable 668270-12-0 10096344
50
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829

Interventional clinical trials:

(show top 50) (show all 1963)
# Name Status NCT ID Phase Drugs
1 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
2 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
3 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
4 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
5 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
6 Arterial Catheter to Monitor Glycemia Unknown status NCT01176279 Phase 4
7 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
8 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4 Commercial Hylenex® recombinant (hyaluronidase human injection);Precommercial Hylenex recombinant (hyaluronidase human injection);Insulin lispro;Insulin aspart;Insulin glulisine
9 A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
10 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
11 Obtain a Good Blood Glucose Control With the Paradigm Real Time System Unknown status NCT00441129 Phase 4
12 The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients Unknown status NCT01270191 Phase 4 Exenatide;Humulin-N
13 Insulin Infusion Diabetes Ulcer Unknown status NCT00700154 Phase 4
14 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
15 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
16 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
17 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
18 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
19 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
20 Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes. Unknown status NCT00254085 Phase 4 Insulin Aspart
21 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
22 Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Unknown status NCT00259168 Phase 4 Nateglinide
23 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
24 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4 Insulin NovoRapid versus Actrapid
25 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
26 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
27 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
28 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4 2 different procedures of administration of insulin
29 Comparison Study of Insulin Glargine and NPH Insulin Unknown status NCT01854723 Phase 4 Switching to NPH insulin;Continuation of insulin glargine
30 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
31 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
32 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
33 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
34 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
35 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
36 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
37 Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock Completed NCT02266264 Phase 4 Hydrocortisone
38 Sitagliptin in Non-Diabetic Patients Undergoing General Surgery Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
39 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
40 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
41 Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
42 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
43 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed NCT01810952 Phase 4 Glargine insulin;Lispro insulin;NPH Insulin
44 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
45 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery Completed NCT01545700 Phase 4 Control-saline;Dexamethasone 4 mg;Dexamethasone 8 mg;Control saline;Dexamethasone 4 mg;Dexamethasone 8 mg
46 Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates Completed NCT01419873 Phase 4 Actrapid Human Insulin
47 Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
48 A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro
49 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
50 Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Completed NCT02253121 Phase 4 Dapagliflozin;Sliding scale insulin

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperglycemia

Sources

Genetic Tests for Hyperglycemia

About this section

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 29
Sources

Anatomical Context for Hyperglycemia

About this section

MalaCards organs/tissues related to Hyperglycemia:

41
Endothelial, Heart, Testes, Pancreas, Liver, Brain, Kidney
Sources

Publications for Hyperglycemia

About this section

Articles related to Hyperglycemia:

(show top 50) (show all 1396)
# Title Authors Year
1
Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients. ( 29407052 )
2018
2
Baicalin administration attenuates hyperglycemia-induced malformation of cardiovascular system. ( 29445081 )
2018
3
Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. ( 29966984 )
2018
4
Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia. ( 29402990 )
2018
5
Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. ( 29923016 )
2018
6
Hyperglycemia Alters the Structure and Hemodynamics of the Developing Embryonic Heart. ( 29439517 )
2018
7
Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. ( 29951281 )
2018
8
Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial. ( 29951978 )
2018
9
Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. ( 29910582 )
2018
10
Correlation of hyperglycemia with mortality after acute ischemic stroke. ( 29399044 )
2018
11
Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report. ( 29911051 )
2018
12
Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction. ( 29391151 )
2018
13
Maternal vitamin D and neonatal anthropometrics and markers of neonatal glycaemia: Belfast Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. ( 29936925 )
2018
14
Impact of varying levels of hyperglycemia on clinicoradiographic outcomes after endovascular reperfusion treatment. ( 29959399 )
2018
15
ULK1-regulated autophagy: A mechanism in cellular protection for ALDH2 against hyperglycemia. ( 29128638 )
2018
16
Hyperglycemia and diabetes mellitus are related to vestibular organs dysfunction: truth or suggestion? A literature review. ( 29936650 )
2018
17
Could the stress hyperglycemia ratio predict the clinical outcomes of coronary artery disease patients after percutaneous coronary intervention? ( 29407118 )
2018
18
Individuals with Type 1 and Type 2 Diabetes Mellitus Trade Increased Hyperglycemia for Decreased Hypoglycemia When Glycemic Variability is not Improved. ( 29164512 )
2018
19
Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia. ( 29895835 )
2018
20
Hyperglycemia attenuates the association between telomere length and age in Ukrainian population. ( 29958997 )
2018
21
Melatonin attenuates smoking-induced hyperglycemia via preserving insulin secretion and hepatic glycogen synthesis in rats. ( 29437243 )
2018
22
Hyperglycemia-Driven Neuroinflammation Compromises BBB Leading to Memory Loss in Both Diabetes Mellitus (DM) Type 1 and Type 2 Mouse Models. ( 29974394 )
2018
23
Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in Japanese patients with early stage of type 2 diabetes. ( 29406607 )
2018
24
PPAR-I+ Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System. ( 29433142 )
2018
25
Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria. ( 29897925 )
2018
26
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway. ( 29435181 )
2018
27
Hyperglycemia is associated with cardiac complications in elderly nondiabetic patients receiving total parenteral nutrition. ( 29419661 )
2018
28
Hyperglycemia decreases anti-cancer efficiency of Adriamycin via AMPK pathway. ( 29941677 )
2018
29
Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress. ( 29392616 )
2018
30
Abdominal circumference profiles of macrosomic infants born to mothers with or without hyperglycemia in China. ( 29886780 )
2018
31
Hyperglycemia induces epithelial-mesenchymal transition in the lungs of experimental diabetes mellitus. ( 29934127 )
2018
32
Effect of Hyperglycemia on Purinergic and Nitrergic Inhibitory Neuromuscular Transmission in the Antrum of the Stomach: Implications for Fast Gastric Emptying. ( 29410956 )
2018
33
Pulsatile hyperglycemia increases insulin secretion but not pancreatic I^-cell mass in intrauterine growth-restricted fetal sheep. ( 29973299 )
2018
34
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. ( 29890391 )
2018
35
Short and Sweet: A commentary on short sleep duration and hyperglycemia in pregnancy. ( 29887257 )
2018
36
Perspectives on diagnostic strategies for hyperglycemia in pregnancy - dealing with the barriers and challenges in South Asia. ( 29408685 )
2018
37
Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection. ( 29894743 )
2018
38
The association between famine exposure in early life and type 2 diabetes and hyperglycemia in adulthood: results from the China health and retirement longitudinal study (CHARLS). ( 29451367 )
2018
39
Hyperglycemia in Acute Coronary Syndromes: From Mechanisms to Prognostic Implications. ( 29407051 )
2018
40
Hyperglycemia-induced mouse trophoblast spreading is mediated by reactive oxygen species. ( 29392783 )
2018
41
NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. ( 28436035 )
2018
42
Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy. ( 28575322 )
2017
43
Glycosuria and hyperglycemia in the neonatal period as the first clinical sign of Fanconi-Bickel syndrome. ( 28493372 )
2017
44
MiR-29c/PRKCI Regulates Axonal Growth of Dorsal Root Ganglia Neurons Under Hyperglycemia. ( 28070856 )
2017
45
Stress induced hyperglycemia after spontaneous subarachnoid hemorrhage and its role in predicting cerebrospinal fluid diversion. ( 28089808 )
2017
46
Ser1928 phosphorylation by PKA stimulates the L-type Ca2+ channel CaV1.2 and vasoconstriction during acute hyperglycemia and diabetes. ( 28119464 )
2017
47
Coexistence of GH-Producing Pituitary Macroadenoma and Meningioma in a Patient with Multiple Endocrine Neoplasia Type 1 with Hyperglycemia and Ketosis as First Clinical Sign. ( 29225978 )
2017
48
Diagnostic protocol for gestational diabetes mellitus (GDM) (IADPSG/ADA, 2011): influence on the occurrence of GDM and mild gestational hyperglycemia (MGH) and on the perinatal outcomes. ( 28053673 )
2017
49
Stress hyperglycemia and acute ischemic stroke in-hospital outcome. ( 28081783 )
2017
50
Diffuse (18)F-FDG accumulation in the subarachnoid space detected by PET/CT in a patient with subarachnoid hemorrhage and hyperglycemia. ( 28064344 )
2017